Mary Anne brings to the Board extensive knowledge of both the VCT and growth capital investment sectors, having been an advisor to or executive of innovative companies in the healthcare and technology sectors for over twenty years. Mary Anne served as a non-executive Director of Albion Technology & General VCT Plc (“AATG”) from 2013 until 2023, following its merger with Albion Income & Growth VCT Plc where she had served as a non-executive Director from 2004. Mary Anne is also the Founder and Managing Director of Science to Business Limited which specialises in advising medical technology businesses on fundraising and commercialisation strategy. Prior to this Mary Anne had a fifteen-year career in international corporate finance as a M&A Investment Banker at Goldman Sachs International Limited, Vice President at Bankers Trust Company and Managing Director of Paribas’ Financial Institutions Group. Mary Anne holds a MA (Hons) in Chemistry from the University of Oxford and is a member of the University of Oxford’s Department of Chemistry Development Board.
You should only rely on the information provided in the Prospectus and relevant Key Information Document when deciding whether to make an investment. Your capital is at risk and you may get back less than you invest.
Seneca Growth Capital VCT Plc (previously Hygea vct plc) is incorporated in England and Wales. The company’s main country of operation is the United Kingdom. The company is an alternative investment fund under the AIF Regulations 2013. Seneca Growth Capital VCT Plc’s registered office is at 9 The Parks, Haydock, Merseyside, WA12 0JQ (Company No. 04221489). Seneca Partners Limited (Company No. 07196273) is Authorised and Regulated by the Financial Conduct Authority (FRN 583361). Seneca Partners Limited’s registered office is at 9 The Parks, Haydock, WA12 0JQ.